Protagonist Therapeutics, Inc.: Clinical Response and Durabi

Protagonist Therapeutics, Inc.: Clinical Response and Durability of Response of Rusfertide in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the L

NEWARK, CA / ACCESSWIRE / June 9, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") announced today that Ronald Hoffman, MD, Icahn School of Medicine at Mount Sinai,

Related Keywords

Marina Kremyanskaya , Jami Taylor , Arturo Molina , Ronald Hoffman , Protagonist Therapeutics Inc View , European Hematology Association , Exchange Commission , Nasdaq , Protagonist Therapeutics Inc , Icahn School Of Medicine At Mount Sinai , Protagonist Therapeutics , Icahn School , Mount Sinai , Targeted Therapy , Uncontrolled Erythrocytosis , Polycythemia Vera , Hepcidin Mimetic , Randomized Withdrawal Results , Chief Medical Officer , Private Securities Litigation Reform Act , Janssen Biotech , Inc View , Protagonist , Herapeutics , Linical , Response , Durability , Rusfertide , Polycythemia , Vera , Featured , Oday , Dress , Briefing , Plans , Follow , Ear , Extension , Study , Nable , Urther , Evaluation ,